Brii Biosciences Limited (HK:2137) has released an update.
Brii Biosciences Limited has entered into a significant transaction to acquire assets and licenses related to BRII-179 and PreHevbri from VBI and K2 parties. This agreement, which involves an exclusive license for Hepatitis B prevention technology and a purchase of related assets, marks a strategic move for the company in the biotech field. Investors are advised to stay informed about the transaction’s completion conditions.
For further insights into HK:2137 stock, check out TipRanks’ Stock Analysis page.